Summary:
- The article discusses concerns about the CDC's handling of the approval process for a new RSV (respiratory syncytial virus) antibody treatment for infants.
- It suggests that the CDC may have provided misleading information to its advisory committee, potentially downplaying the risks and overestimating the benefits of the treatment.
- The article raises questions about the transparency and decision-making process involved in the approval of this new medical treatment for vulnerable infants.